$2.83
10.55% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US00091E1091
Symbol
ABSI

Absci Corp Stock price

$2.83
-1.24 30.47% 1M
-1.38 32.78% 6M
-1.37 32.62% YTD
+1.44 103.60% 1Y
-8.41 74.82% 3Y
-13.17 82.31% 5Y
-13.17 82.31% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.27 10.55%
ISIN
US00091E1091
Symbol
ABSI
Sector
Industry

Key metrics

Market capitalization $325.04m
Enterprise Value $194.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 46.12
P/S ratio (TTM) P/S ratio 77.21
P/B ratio (TTM) P/B ratio 1.61
Revenue growth (TTM) Revenue growth -39.35%
Revenue (TTM) Revenue $4.21m
EBIT (operating result TTM) EBIT $-103.35m
Free Cash Flow (TTM) Free Cash Flow $-70.76m
Cash position $142.87m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 54.16
EV/Sales forward 32.35
Short interest 16.43%
Show more

Is Absci Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Absci Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Absci Corp forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Absci Corp forecast:

Buy
86%
Hold
14%

Financial data from Absci Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.21 4.21
39% 39%
100%
- Direct Costs 14 14
3% 3%
324%
-9.43 -9.43
32% 32%
-224%
- Selling and Administrative Expenses 23 23
4% 4%
547%
- Research and Development Expense 57 57
22% 22%
1,360%
-90 -90
17% 17%
-2,131%
- Depreciation and Amortization 14 14
3% 3%
324%
EBIT (Operating Income) EBIT -103 -103
14% 14%
-2,455%
Net Profit -98 -98
8% 8%
-2,320%

In millions USD.

Don't miss a Thing! We will send you all news about Absci Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Absci Corp Stock News

Neutral
Seeking Alpha
14 days ago
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Di...
Neutral
GlobeNewsWire
14 days ago
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
Neutral
GlobeNewsWire
19 days ago
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
More Absci Corp News

Company Profile

AbSci Corp. engages in the development of protein biomanufacturing technology. It offers SoluPro, an all-in-one protein expression platform which produces complex proteins using simplest and least expensive organism. The company was founded by Sean Mcclain and Mark Valasek in 2011 and is headquartered in Vancouver, WA.

Head office United States
CEO Sean McClain
Employees 156
Founded 2011
Website www.absci.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today